Phase 1 N=25 An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode
Herpes Labialis
Primary: Mean Change From Baseline in Blood Flow — 2558.65; 3470.13; 809.88; 960.86 Perfusion Units — p=0.3061
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=775 Phase 3 Clinical Study for the Treatment of Cold Sore
Herpes Labialis
Primary: Time to Healing (TTH) of Vesicular Primary Lesion — 7.00; 7.32 Days — p=0.015
Phase 2 N=158 Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores
Oral Herpes Simplex
Primary: Number of Participants for Whom a Recurrent Oral Herpes Episode Initiated With Prodromal Symptoms Were Aborted Before Progressing to a Lesion as Assessed by a Trained…
Phase 4 N=126 A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers
Cold Sore
Primary: Clinical Assessment Performed by the Investigator and Skin Temperature at the Cold Sore. — 39; 32 participants
Phase 1 N=36 Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)
HSV · Herpes Labialis
Primary: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline — 10.073; 11.380; 10.711; 11.431 q-RT-PCR crossing threshold cycle (Ct)
Phase 3 N=157 Zinc for the Treatment of Herpes Simplex Labialis (HSL)
Herpes Simplex Labialis
Primary: Zicam Was Compared to Placebo as a Treatment of Recurrent HSL From the Date and Time of the Initiation of Therapy Until the Date and Time of Resolution of the Lesion or…
Phase 3 N=4,076 Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
Herpes Labialis
Primary: Lesion Healing — 107.47; 110.08; 112.41 hours
Phase 3 N=2,020 A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally
Recurrent Herpes Labialis
Primary: Duration of Episode (DOE) Was Measured in Hours (Using the Science 37 Platform), of a Single Treated Herpes Labialis (HL) Lesion — 66.5; 73.6 Hours — p=0.716
Phase 1 N=54 Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis
Herpes Labialis
Primary: Subjects With at Least One Form of Contact With Study Staff With no Herpes Labialis Outbreaks Within 119 Days of Sensitization — 62.96; 20 percentage of particpants
Phase 2 N=173 Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores
Recurrent Herpes Labialis
Primary: Clinician Assessed Duration of Complete Healing of the Herpetic Episode — 129.6; 154.6 hours
Phase 2 N=451 Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for Episodic Treatment of Cold Sores
Recurrent Herpes Labialis
Primary: Clinician Assessed Duration of the Classical Herpetic Lesion — 162.7; 163.6 hours
Phase 2 N=10 EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions
Herpes Simplex Oral
Primary: Duration (Days) of Herpes Labialis Outbreak Until Healed — 10.6; 8.25 days
Phase 3 N=54 Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old
Herpes Labialis
Primary: Reporting of Adverse Events — 9 participants
Phase 2 N=19 Herpes Simplex Type 1 Suppression in Hepatitis C
Chronic Hepatitis C Infection
Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05
Phase 2 N=242 Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection
Oral Herpes Simplex
Primary: Proportion of Subjects Who Experience a New Cold Sore Outbreak That Proceeds to the Lesion Stage. Of Those Subjects That Take Study Medication (Experience a New Emerging…
Phase 3 N=29 Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth
Herpes Simplex
Primary: Participants With Neurologic Impairment at 12 Months as Measured by a Bayley's Neuro-developmental Assessment.(Motor Scores) — 0; 3; 0; 0 Participants
N/A N=46 Evaluation of ColdZyme® Mouth Spray on Prevention and Alleviation of Rhinovirus Induced Common Cold
Common Cold
Primary: Reduction in Viral Load in the URT — 3.6; 3.3; 4.9; 4.1 log 10 copies/mL — p=0.7146
Phase 3 N=250 Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.
Sore Throat Due to a Common Cold
Primary: Change From Baseline Sore Throat Pain Intensity — -27.4; -26.9 mm
Phase 2 N=223 Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
Herpes Labialis
Primary: Efficacy Measured by Percentage of Subjects With Non-ulcerative Lesions Based on Principal Investigator's Assessment — 21.8; 16.4; 19.9; 78.2 percentage of partcipants…
Phase 2 N=139 Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis
Herpes Labialis · Cold Sore
Primary: Days to Next Herpes Labialis (Cold Sore) Episode From 43 Days After the First Dose up to 121 Days After the First Dose — 128; 163; 174 days
Phase 4 N=383 A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
Herpes Genitalis
Primary: Percentage of Participants With Time to First GH Recurrence — 43; 71 Percentage of participants — p=<0.001
Phase 3 N=275 Open-label Study of ASP2151 in Herpes Simplex Patients
Herpes Simplex
Primary: Percentage of Participants With Healing by Day 8 — 194 Participants
N/A N=46 The VIBLOK SAfety and perFormancE Trial
HSV-2 Infection · Genital Herpes
Primary: Serious Adverse Device Effects — 0 Percentage SADE's
Phase 2 N=31 Cold Urticaria Treatment With Xolair
Cold Contact Urticaria
Primary: Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo — -10.6; -10.4; -0.3 degree celcius — p=0.001
N/A N=543 Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms
Common Cold
Primary: Number of Days With at Least Moderate (i.e. Moderate or Severe) Common Cold Symptoms. — 7.6; 9.5 Number of days — p=0.023
N/A N=33 The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years
Upper Respiratory Infection · Common Cold
Primary: Local Leukotriene Levels — 440; 368; 440; 619 pg/ml
Phase 2 N=411 Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses
Common Cold
Primary: The Primary Efficacy Endpoint of This Study is the Incidence of Cold Illnesses. — 47.1; 43.9 cold illnesses per 100 subjects — p=>0.5000
Phase 4 N=463 Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients
Genital Herpes
Primary: Investigator Assessed Time to Healing of All Non-aborted Genital Herpes Lesions — 5.38; 4.79 Days — p=0.4161
Phase 2 N=146 A Nasal Spray With Glucose Oxidase as a Treatment of Common Cold
Common Cold
Primary: Reducing Symptoms of a Common Cold — 53; 53; 55; 54 units on a scale
N/A N=88 GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women
Genital Herpes
Primary: Time to Healing of Genital Lesions — 5.1; 6.0 Days